February 7, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares over potential securities laws violations by Catabasis Pharmaceuticals Inc and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) concerning whether a series of statements by Catabasis Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambrdige, Ma based Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. Catabasis Pharmaceuticals Inc went public in June 2016. Shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) reached $14.38 per share in July 2016.

On January 31, 2017, Catabasis Pharmaceuticals Inc announced top-line safety and efficacy results for Part B of the MoveDMD trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD).

Shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) declined to as low as $1.08 per share on February 1, 2017.

On February 7, 2017, NASDAQ:CATB shares closed at $1.22 per share.